Brought to you by 
Anacor gets $50mm including investments from GSK, Schering
29 Jan 2009
Executive Summary
Just two weeks after withdrawing its IPO, Anacor Pharmaceuticals (developing compounds for fungal, bacterial, and inflammatory diseases) raised $50mm through the sale of preferred shares to returning shareholders Rho Capital Partners, Venrock Associates, Care Capital, and Aberdare Ventures. Also contributing were GlaxoSmithKline and Schering to fulfill obligations as part of separate 2007 licensing agreements with Anacor. The company will use the proceeds for ongoing development of its boron chemistry-based candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com